{
  "ticker": "LLY",
  "target_date": "2025-05-06",
  "actual_date": "2025-05-06",
  "collected_at": "2025-12-08T11:43:43.444352",
  "price": {
    "open": 812.24,
    "high": 813.76,
    "low": 765.96,
    "close": 770.707275390625,
    "volume": 5982000,
    "change_1d_pct": -5.64,
    "change_7d_pct": -12.37,
    "change_30d_pct": -10.38
  },
  "technicals": {
    "rsi_14": 52.1,
    "sma_20": 801.15,
    "sma_50": 824.36,
    "macd": 4.094,
    "macd_signal": 5.909,
    "macd_histogram": -1.815,
    "bb_upper": 917.34,
    "bb_lower": 684.96,
    "price_vs_sma20_pct": -3.8,
    "price_vs_sma50_pct": -6.51,
    "volume_ratio": 1.3
  },
  "fundamentals": {
    "market_cap": 890082951168,
    "pe_ratio": 48.647232,
    "forward_pe": 43.81686,
    "price_to_book": 37.382908,
    "price_to_sales": 14.9795685,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.71,
    "pct_from_52w_low": 59.17
  },
  "macro": {
    "spy": {
      "price": 555.61,
      "change_1d_pct": -0.84,
      "change_7d_pct": 1.44
    },
    "vix": {
      "level": 24.76,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.31
    },
    "dollar_index": {
      "level": 99.24
    },
    "gold": {
      "price": 3411.4
    },
    "regime": "SIDEWAYS"
  },
  "news": [
    {
      "headline": "Eli Lilly (NYSE:LLY) Declares US$1.50 Second Quarter Dividend For 2025",
      "source": "Yahoo",
      "datetime": 1746553751,
      "summary": "Eli Lilly (NYSE:LLY) experienced an 11% share price increase over the past month, largely influenced by the affirmation of a $1.50 per share dividend declared for the second quarter. The announcement of Q1 earnings, showing significant revenue growth to $12,729 million, and promising results from th",
      "url": "https://finnhub.io/api/news?id=b1f795fd9faa811322f1a0667bb6e8103cc38abadf421a5736fd04046fbba338"
    },
    {
      "headline": "Eli Lilly signs $415m deal for Alchemab\u2019s ALS therapy",
      "source": "Yahoo",
      "datetime": 1746549487,
      "summary": "The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.",
      "url": "https://finnhub.io/api/news?id=59539d0bc527239456c9356fc7f0baf3d623d5b77105a2f6654b090f8dff5b72"
    },
    {
      "headline": "Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra",
      "source": "SeekingAlpha",
      "datetime": 1746548400,
      "summary": "Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I recommend buying the stock.",
      "url": "https://finnhub.io/api/news?id=5f387c072cc8bfec0a13d281819b5c3f13b0d6721c90f26b0b47b81150baf60a"
    },
    {
      "headline": "Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip?",
      "source": "Yahoo",
      "datetime": 1746540000,
      "summary": "Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged.  The company's GLP-1 drugs continue to drive strong revenue growth.  Mounjaro is approved by the Food and Drug Administration (F",
      "url": "https://finnhub.io/api/news?id=3a2060c30b03646ef801c332a812ff0589a290bbcec367fe4544109ae49a65c4"
    },
    {
      "headline": "Mutual Funds Gobble Up Eli Lilly Stock, Ge Vernova And A Wrestling Name",
      "source": "Yahoo",
      "datetime": 1746539838,
      "summary": "Institutional backing is an important element of a winning stock, as large purchases by big money managers can help boost stock prices.  Investor's Business Daily's Stocks That Funds Are Buying screen identified 21 leading names, including Eli Lilly, GE Vernova and TKO Group Holdings.  Eli Lilly sto",
      "url": "https://finnhub.io/api/news?id=e245d675c9e4ac145cd7937e0b15156e8fa703bc3a97626d95de03d208b87b44"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746476222.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000134/xslF345X05/wk-form4_1746476222.xml"
    },
    {
      "form": "10-Q",
      "date": "2025-05-01",
      "description": "lly-20250331.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/lly-20250331.htm"
    },
    {
      "form": "8-K",
      "date": "2025-05-01",
      "description": "lly-20250501.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/lly-20250501.htm"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353361.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000124/xslF345X05/wk-form4_1745353361.xml"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353273.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000122/xslF345X05/wk-form4_1745353273.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}